【Abstract】Cervical cancer is one of the three gynecological malignancies, its high incidence, high recurrence rate and high transfer rate makes a lot of research. Research has clearly confirmed that infection of persistent human papilloma virus (HPV) especially the high-risk HPV infection is the major cause of cervical cancer. The most commonly used treatments include：surgery, radiotherapy, chemotherapy, immunetherapy, etc. The HPV gene vaccine, particularly in the target of E7 gene, can induce an specific immune response to control tumor growth and it has been been a researchShotspot on the treatment of cervical cancer[1]. But there is often a problem of reduced immunogenicity of gene vaccine when it is applied to the human body. Using IL-15 gene as a vaccine adjuvant to promote antigen-specific immune responses can significantly improve immunogenicity[2]. The prospect of IL-15 combined with HPV gene vaccine in the treatment of cervical cancer is reviewed and the feasibility of its application and the value of immunotherapy in the treatment of cervical cancer are discussed after consulting literature.